SCHV vs XBI
Schwab US Large-Cap Value ETF vs SPDR S&P Biotech ETF
- • SCHV has the lower expense ratio at 0.04% vs 0.35% for XBI.
- • SCHV pays a higher dividend yield (1.81%).
Side-by-side metrics
| Metric | SCHV | XBI |
|---|---|---|
Expense ratio Annual fee. Lower is better. | 0.04% | 0.35% |
Dividend yield Trailing 12-month yield. | 1.81% | 0.35% |
AUM Assets under management — bigger funds are typically more liquid. | $15.68B | $10.92B |
YTD return | 18.70% | 28.80% |
1-year return | — | — |
3-year return Annualized. | — | — |
5-year return Annualized. | — | — |
10-year return Annualized. | — | — |
Beta (3Y) Volatility relative to the market. Closer to 1 = market-like. | 0.73 | 1.01 |
P/E ratio | 20.43 | — |
Last price | $34.95 | $156.41 |
Inception | — | — |
Issuer | Schwab | State Street |
SCHV top holdings
| BRK-B | Berkshire Hathaway Inc Class B | 3.32% |
| JPM | JPMorgan Chase & Co | 2.95% |
| XOM | ExxonMobil Holdings Corp | 2.53% |
| JNJ | Johnson & Johnson | 2.16% |
| WMT | Walmart Inc | 1.81% |
| ABBV | AbbVie Inc | 1.71% |
| CVX | Chevron Corp | 1.53% |
| CSCO | Cisco Systems Inc | 1.35% |
| PG | Procter & Gamble Co | 1.23% |
| MRK | Merck & Co Inc | 1.21% |
XBI top holdings
| MRNA | Moderna Inc | 2.37% |
| NTRA | Natera Inc | 1.82% |
| HALO | Halozyme Therapeutics Inc | 1.77% |
| TWST | Twist Bioscience Corp | 1.77% |
| BIIB | Biogen Inc | 1.75% |
| AMGN | Amgen Inc | 1.73% |
| EXEL | Exelixis Inc | 1.73% |
| UTHR | United Therapeutics Corp | 1.72% |
| ABBV | AbbVie Inc | 1.71% |
| GILD | Gilead Sciences Inc | 1.70% |
About SCHV
SCHV (Schwab US Large-Cap Value ETF) is Large-cap US value at low cost. Managed by Schwab, the fund carries $15.7B in assets under management, an expense ratio of 0.04%, a dividend yield of 1.81%. Its largest holding is Berkshire Hathaway Inc Class B (BRK-B), which represents 3.3% of the portfolio. Real Estate is the fund's largest sector exposure at 4.0%.
About XBI
XBI (SPDR S&P Biotech ETF) is Equal-weight biotech stocks in the S&P Biotech Index. Managed by State Street, the fund carries $10.9B in assets under management, an expense ratio of 0.35%, a dividend yield of 0.35%. Its largest holding is Moderna Inc (MRNA), which represents 2.4% of the portfolio. Financial Services is the fund's largest sector exposure at 0.6%.